June 22, 2021
Markets

PROVECTUS BIOPHARMACEUTICALS : MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS. (form 10-Q)

The following discussion is intended to assist in the understanding and
assessment of significant changes and trends related to our results of
operations and our financial condition together with our consolidated
subsidiaries. This discussion and analysis should be read in conjunction with
the accompanying unaudited condensed financial statements and our Annual Report
on Form 10-K for the year ended December 31, 2020 filed with the SEC on March 2,
2021 ("2020 Form 10-K"), which includes additional information about our
critical accounting policies and practices and risk factors. Historical results
and percentage relationships set forth in the consolidated statement of
operations, including trends which might appear, are not necessarily indicative
of future operations.



Overview



Provectus is a clinical-stage biotechnology company developing immunotherapy
medicines based on an...

Read full article…